AstraZeneca, BMY To Target Disease Management And Primary Care Synergies With Amylin Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
In acquiring Amylin at a hefty premium, Bristol-Myers Squibb and its partner AstraZeneca are highly optimistic about prospects for Amylin’s GLP-1 franchise, and also hope to leverage their existing infrastructure as their fledgling diabetes franchise struggles to meet expectations.
You may also be interested in...
Focusing R&D In The Age Of Speed: An Interview With Bristol-Myers Squibb CSO Francis Cuss
Since being promoted to chief scientific officer of Bristol-Myers Squibb, effective July 2013, company veteran Francis Cuss says he has aimed for continuity while staying flexible to respond to breaking science. In an interview at the J.P. Morgan Healthcare Conference in January, he explains the company’s thinking when it comes to focusing on particular disease areas with the highest unmet need and potential for speedy development.
Patent Cliff Continues in 2014, But Not So Steeply
Most of big pharma has crossed to the other side of the patent cliff and put their biggest losses behind them in 2012 and 2013, but a few major blockbusters will face new generic competition this year, including Nexium, Copaxone, and Nasonex.
What To Do With $3.4 Billion? Deals And Dividends Says BMS’ Andreotti
BMS plans to use the $3.4 billion it will receive shortly from AstraZeneca for selling its stake in their diabetes JV to fund a dividend increase, business development and possibly a share repurchasing program, Andreotti tells investors at the Goldman Sachs meeting.